2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia
5
Neoplasms, Plasma Cell
4
Lymphoma
4
Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Infections
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Congenital Abnormalities
2
Sezary Syndrome
1
Primary Myelofibrosis
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Paraneoplastic Syndromes
1
Neuroblastoma
1
Mycosis Fungoides
1
Myasthenia Gravis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
plerixafor
2
Lenalidomide
2
ofatumumab
1
gamma-Globulins
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Saline Solution
1
SARS-CoV-2 inactivated vaccines
1
Panzyga
1
Influenza Vaccines
1
Immunoglobulins
1
Hizentra
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Agammaglobulinemia
×
gamma-Globulins
×
Clear all
NCT05645107
2026-04-13
EXCELL
Grifols Therapeutics LLC
Phase 3
Recruiting
386 enrolled